Literature DB >> 14707286

p53-independent functions of MDM2.

Gitali Ganguli1, Bohdan Wasylyk.   

Abstract

The tumor suppressor p53 is inactivated by overexpression of MDM2 in about 10% of human tumors. However, p53 is inactivated by other mechanisms in the majority of tumors, raising the possibility that MDM2 may be irrelevant to transformation in most cases. However, MDM2 has been reported to have p53-independent functions, in cell cycle control, differentiation, cell fate determination, DNA repair, basal transcription, and other processes. Furthermore, MDM2 appears to contribute to the transformed phenotype in the absence of wild-type p53. Nevertheless, the number of studies is still limited, and the evidence in some cases does not unequivocally show that the functions are p53 independent. We will discuss the circuits of regulation involving MDM2 that do not directly concern p53. Hopefully, future work will consolidate our understanding of the p53-independent pathological functions of MDM2 and will lead to useful therapeutic interventions that target the majority of tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14707286

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  56 in total

1.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication.

Authors:  Taisuke Izumi; Katsuhiro Io; Masashi Matsui; Kotaro Shirakawa; Masanobu Shinohara; Yuya Nagai; Masahiro Kawahara; Masayuki Kobayashi; Hiroshi Kondoh; Naoko Misawa; Yoshio Koyanagi; Takashi Uchiyama; Akifumi Takaori-Kondo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-11       Impact factor: 11.205

3.  Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation.

Authors:  Chiharu Uchida; Seiichi Miwa; Kyoko Kitagawa; Takayuki Hattori; Tomoyasu Isobe; Sunao Otani; Toshiaki Oda; Haruhiko Sugimura; Takehiko Kamijo; Keizou Ookawa; Hideyo Yasuda; Masatoshi Kitagawa
Journal:  EMBO J       Date:  2004-12-02       Impact factor: 11.598

4.  A function for the RING finger domain in the allosteric control of MDM2 conformation and activity.

Authors:  Bartosz Wawrzynow; Susanne Pettersson; Alicja Zylicz; Janice Bramham; Erin Worrall; Ted R Hupp; Kathryn L Ball
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

Review 5.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

Authors:  James J Manfredi
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

Review 6.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

7.  HDM2-binding partners: interaction with translation elongation factor EF1alpha.

Authors:  Rebecca Frum; Scott A Busby; Mahesh Ramamoorthy; Sumitra Deb; Jeffrey Shabanowitz; Donald F Hunt; Swati P Deb
Journal:  J Proteome Res       Date:  2007-03-21       Impact factor: 4.466

8.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Authors:  Maria Maguire; Paul C Nield; Timothy Devling; Rosalind E Jenkins; B Kevin Park; Radoslaw Polański; Nikolina Vlatković; Mark T Boyd
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 9.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

10.  Splicing up mdm2 for cancer proteome diversity.

Authors:  Danielle R Okoro; Melissa Rosso; Jill Bargonetti
Journal:  Genes Cancer       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.